AD 6626

Drug Profile

AD 6626

Alternative Names: AD-6626

Latest Information Update: 16 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Stanford University
  • Developer ALDEA Pharmaceuticals; Stanford University
  • Class Antianaemics; Small molecules
  • Mechanism of Action Aldehyde dehydrogenase 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alcoholism
  • Preclinical Fanconi's anaemia

Most Recent Events

  • 16 Jul 2015 ALDEA Pharmaceuticals plans a phase I trial in healthy volunteers in Australia (ACTRN12615000601538)
  • 20 Jan 2015 Phase-I clinical trials in Alcoholism in Australia (IV)
  • 18 Dec 2014 Clinical trials in Alcoholism (In volunteers) in Australia (IV) (ACTRN12614001333606)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top